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Cofactor of BRCA1 (COBRA1) was first identified as a protein that binds to the breast cancer susceptibility gene 
product BRCA1. COBRA1 modulates estrogen-dependent and independent transcription and suppresses the 
growth of breast cancer cells. Its expression is significantly reduced in metastatic and recurrent breast cancer, 
pointing to a tumor suppressor function in breast cancer development. In light of these initial implications of 
COBRA1 in human breast cancer, the current investigation sought to obtain more direct functional evidence that 
links COBRA1 with BRCA1 in transcriptional regulation in breast cancer cells.  Small hairpin RNA 
(shRNA)-mediated gene knockdown and gene expression microarray were used to study the impact of COBRA1 
and BRCA1 on global transcription in the same breast cancer cell background. The gene expression profiling 
study in tissue culture cells uncovers a significant overlap of COBRA1- and BRCA1-regulated genes, many of 
which have been previously implicated in breast cancer progression. The data shown herein support the notion 
that COBRA1 and BRCA1 may engage in common gene regulatory pathways to suppress breast cancer 
progression. 
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1.  Introduction 
Cofactor of BRCA1 (COBRA1) was first 
identified through a yeast two-hybrid screen as a 
protein that binds to the BRCT domain of the tumor 
suppressor BRCA1 [1]. In support of its role in 
transcriptional regulation, COBRA1 is found in the 
negative elongation factor (NELF) complex, which 
stalls RNA polymerase II (RNAPII) during 
transcription elongation in vitro [24]. Furthermore, in 
vivo studies also demonstrate that COBRA1 and the 
rest of the NELF complex are recruited to distinct 
regions of the genome and modulate both 
estrogen-dependent and -independent expression of 
cancer-associated genes in breast cancer cell lines [5,6]. 
Consistent with the in vitro biochemical finding, 
COBRA1 modulates the movement of the 
transcription elongation complex at several 
estrogen-responsive transcription promoters in vivo, 
thus distinguishing itself from most of the known 
transcription coregulators that act at the transcription 
initiation stage [5]. 
  COBRA1 is enriched in the luminal epithelial 
cells of normal mammary gland [5], and COBRA1 
mRNA level has been reported to fluctuate in various 
b r e a s t  c a n c e r  c e l l  l i n e s  [ 7 ] .  I n  a d d i t i o n ,  e c t o p i c  
expression of COBRA1 in breast cancer cells 
suppresses tumor cell proliferation, whereas partial 
depletion of COBRA1 or another NELF subunit 
(NELF-E) results in accelerated cell colony growth [5]. 
In addition, COBRA1 expression was inversely 
correlated with breast cancer progression, with low 
expression in primary tumors from those patients who 
had distant metastasis and local recurrence [29]. These 
observations are consistent with a potential role of 
COBRA1 in tumor suppression. 
Several lines of evidence suggest that COBRA1 
and BRCA1 may share a similar functional pathway(s) 
in transcriptional regulation. First, like COBRA1, 
BRCA1 modulates ligand-dependent and independent 
transcription in ERα-positive breast cancer cells [8,9]. 
Second, both COBRA1 and BRCA1 are physically 
associated with the promoter region of an 
estrogen-responsive gene (pS2/TFF1) [5,9]. Third, 
both proteins interact with the C-terminal domain 
(CTD) of RNAPII as well as several transcription 
elongation factors [10, 13]. Lastly, the two proteins 
also share the property of inducing large-scale 
chromatin reorganization [1]. Therefore, it is 
conceivable that the physical interaction between 
COBRA1 and BRCA1 may facilitate communication 
between the two proteins and thus mutually 
coordinate their regulation of common regulatory Int. J. Biol. Sci. 2007, 3 
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targets in the genome. In the current study, we took a 
genome-wide approach to compare the impact of 
COBRA1 and BRCA1 on global transcription in the 
same breast cancer cell background. Our work led to 
the intriguing finding that COBRA1 and BRCA1 
knockdown resulted in substantially overlapping gene 
expression profiles. Furthermore, a number of 
COBRA1/BRCA1-regulated genes are associated with 
breast cancer progression. 
2.  Materials and Methods 
Cell lines and culture 
T47D cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and 
grown in Dulbecco’s Eagle’s medium supplemented 
with 10% fetal bovine serum, penicillin (100 U/ml) 
and streptomycin (100 μg/ml). Phoenix packaging 
cells were a generous gift from Dr. David Rekosh at 
the University of Virginia. The cell lines were tested to 
be mycoplasma free. 
shRNA constructs 
To generate the stable knockdown cell lines, 
BRCA1 and COBRA1 shRNAs were cloned between 
the BglII and HindIII sites of the 
pSUPER.retro/puromycin and 
pSUPER.retro/neomycin vectors, respectively 
(Oligoengine). The following sequences directed 
against BRCA1 and COBRA1 were used: shBRCA1-03: 
5’-GAAGCCAGCTCAAGCAATA-3’; shCOBRA1-2A: 
5’-GACCTTCTGGAGAAGAGCT-3’. For the negative 
control, the EGFP-targeted shRNA sequence 
(5’-GAACGGCATCAAGGTGAAC-3’) was cloned into 
both the puromycin- and neomycin-resistant 
pSUPER.retro constructs. For verification of the 
BRCA1 knockdown effect, the following siRNA oligos 
were used in a transient transfection experiment: 
BRCA1-DO4 (5’-GCAGATAGTTCTACCAGTA-3’); 
BRCA1-DO7 (5’-GAAGGAGCTTTCATCATTC-3’). 
Viral supernatants were prepared and used to 
infect T47D cells as described previously [5]. Stable 
pools were selected with either 10 μg/ml puromycin 
for one week, or 800 μg/ml neomycin for two weeks. 
To generate the COBRA1/BRCA1 double knockdown 
cells, the BRCA1 single knockdown pool was first 
generated and selected in puromycin-containing 
medium. The selected cell pool was further infected 
with the shCOBRA1-expressing virus, and a second 
selection was carried out for two weeks in the 
presence of both puromycin and neomycin. 
Immunoblotting 
To evaluate the expression of BRCA1 and 
COBRA1, whole cell extracts were prepared in SDS 
sample buffer containing a cocktail of protease 
inhibitors. Protein concentrations were determined by 
the BCA protein assay reagent (Pierce). 
Approximately 30 μg of total protein was used for 5% 
(for BRCA1) or 10% (for COBRA1) SDS-PAGE. The 
proteins were detected by incubation with antibody 
directed against: anti-BRCA1 (Ab1 from Calbiochem), 
anti-tubulin (Calbiochem), or anti-COBRA1 [5]. 
Antibody binding was visualized using 
chemiluminescence (SuperSignal West Pico, Pierce) 
according to the manufacturer’s directions.   
Microarray and data analysis 
shRNA-expressing T47D cells were grown to 
70% confluency and harvested for total RNA. 
Duplicates of the following cell lines were subjected to 
microarray study using the human gene array chips 
(HgU-133A) from Affymetrix: 
shEGFPpuro+shEGFPneo, shBRCA1puro+ 
shEGFPneo, shEGFPpuro+shCOBRA1neo, 
shBRCA1puro+shCOBRA1neo.  
A total of 287 genes were found to be 
differentially regulated by BRCA1 and COBRA1, 
using the LPE test with statistical significance of 
p-value 0.003 [14]. The LPE test is specifically 
designed for small-sample microarray data analysis 
by significantly strengthening statistical power based 
on an advanced error pooling method at each local 
intensity range where signal-to-noise ratio is similar 
among different genes. Thus, by employing LPE, we 
were able to identify differentially regulated genes on 
our duplicated microarray data with statistical rigor.   
Hierarchical clustering analysis was further 
performed with the 287 genes selected in the previous 
analysis, using Pearson correlation as a measure of 
similarity between genes and the average linkage 
(average distance) as a clustering allocation algorithm. 
In this clustering analysis, genes with low-intensity 
expression patterns were found to be closely clustered 
at the left-hand side of the heat map in Fig. 1B. Note 
that high expression intensities are represented by red, 
low expression intensities by green, and medium 
intensities by black. 
RNA isolation and cDNA synthesis 
T47D cells were grown to 70% confluency and to-
tal RNA was extracted with TRIzol Reagent according 
to the manufacturer’s instructions (Invitrogen, Carls-
bad, CA, USA). The concentration and purity of the 
RNA were determined spectrophotometrically at 260 
and 280nm. Approximately 1 μg of RNA was re-
verse-transcribed using ImPromp-II reverse transcrip-
tion system (Promega, Madison, WI, USA). The RNA 
extraction and reverse transcription kits used for 
RNA/cDNA preparation for the clinical samples were 
purchased from AbGene and Sigma, respectively. 
Quantitative real-time PCR 
The Affymetrix microarray results were verified 
by real-time RT-PCR for those genes shown in Fig. 3. 
Primer Express software (Applied Biosystems, Foster 
City, CA, USA) was used to design primers that 
covered two neighboring exons. Primer sequences are 
provided in the Table 1. An ABI 7300 real-time PCR 
machine was used for the quantitative real-time PCR 
analysis. Standard curves were generated by a serial 
d i l u t i o n  o f  c D N A  a n d  r e l a t i v e  m R N A  l e v e l s  w e r e  
measured. Expression levels were normalized against 
β-actin. Results shown were representatives of at least 
three independent experiments.   Int. J. Biol. Sci. 2007, 3 
 
488
 
Figure 1. Microarray analysis of gene expression profiles in COBRA1 and/or BRCA1-depleted breast cancer cell lines. A. 
Immunoblot analysis showing the decreased expression of BRCA1 and COBRA1 protein in the shRNA-expressing T47D cells lines. 
Whole cell extracts were prepared from the following cell lines: shEGFPpuromycin+shEGFPneomycin (E); 
shBRCA1puromycin+shEGFPneomycin (-B); shEGFPpuromycin+shCOBRA1neomycin (-C); and 
shBRCA1puromycin+shCOBRA1neomycin (-B/C). Parental T47D cells (WT) were also included for comparison. Protein 
expression levels were analyzed using antibodies against BRCA1(top panel), COBRA1(middle panel), lamin A/C (bottom panel). 
Lamin was used as a loading control. B. Hierarchical clustering analysis of the 278 COBRA1 and/or BRCA1-regulated genes. Data 
from the duplicates of four knockdown cell lines are shown. High expression intensities are represented by red, while low expression 
intensities are represented by green. Black indicates medium intensities. In the tree dendogram on the left side of the plot, genes with 
similar expression patterns are closely linked in lower levels. On the right side, annotations of corresponding genes were added in the 
order of Affymetrix probe ID, locus ID, gene symbol, and chromosome location.  
Table 1. Primers used in the qRT-PCR for verification of COBRA1/BRCA1-regulated genes. 
Genbank 
Accession No.   
Gene name    Symbol    Primer Forward (5’_3’) Primer Reverse (5’_3’)   
NM_005980   S100 calcium binding protein P   S100P   F 5’-GGAGAAGGAGCTACCAGGC R 
5’-ATCCACGGCATCCTTGTCTT  
NM_003254   Tissue inhibitor of metalloproteinase1   TIMP1   F 5’-ATT CCG ACC TCG TCA TCA GG R 
5’-CTG GTT GAC TTC TGG TGT CCC  
NM_006301   Mitogen-activated protein kinase kinase kinase 
12  
MAP3K12   F 5’-TTG GCA AAG CCT ACT CCA CTG R 
5’-GGA CCT CCC AAA GGT CTT CC  
NM_021903   Gamma-aminobutyric acid (GABA) B receptor, 1  GABBR1   F 5’-CCT CAG AAG GTT GCC AGA TCA R 
5’-TGA TAG CCT TCA CCT GGT CCC  
NM_001547   Apolipoprotein D   APOD   F 5’-CCA GGA GTT GAG AGC TGA TGG R 
5’-GTG GCT TCA CCT TCG ATT TGA  
NM_001547   Apolipoprotein D   APOD   F 5’-CCA GGA GTT GAG AGC TGA TGG R 
5’-GTG GCT TCA CCT TCG ATT TGA  
NM_006846   Serine protease inhibitor, Kazal type, 5   SPINK5   F 5’-GCC ACA GTG TCA GTG CTT CTG R 
5’-GGC AGC ATC TTG TAT GAG GCA  
D13889   Inhibitor of DNA binding 1   ID1   F 5’- GAC GAG CAG CAG GTA AAC GTG R 5’- 
GGC GTG AGT AAC AGC CGT TC  
NM_005380   Neuroblastoma, suppression of tumorigenicity 1  NBL1   F 5’-TCC CTG GTT CAC TGT GAC TCC R 
5’-AAT CTC CCA CAT GGA CTG GG  Int. J. Biol. Sci. 2007, 3 
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3.  Results and Discussion 
Given the known function of COBRA1 in 
transcriptional regulation, it was reasonable to 
speculate that reduced COBRA1 expression might 
lead to aberrant gene expression, which in turn could 
promote tumor recurrence and metastasis. Decreased 
COBRA1 expression may also compromise the 
potential functional interaction between COBRA1 and 
BRCA1. To test these intriguing possibilities, we stably 
knocked down COBRA1 and BRCA1 either separately 
or together in the ER-positive T47D breast cancer cell 
line. As a negative control, we also expressed small 
hairpin RNA (shRNA) specifically targeting at 
enhanced green fluorescent protein (EGFP). 
Immunoblot analysis was carried out to examine the 
expression levels of BRCA1 (Figure 1A, top panel) and 
COBRA1 (middle panel) in these cell pools. When 
compared with the parental T47D cells (lane 5) and the 
EGFP-shRNA control cells (lane 1), both COBRA1 and 
BRCA1 shRNA sequences significantly reduced the 
expression levels of the corresponding proteins in the 
single (lane 2 and 3) and double knockdown cells 
(lane 4). Importantly, the BRCA1 level was not 
affected by the expression of COBRA1-specific 
shRNA, and vice versa. Thus, expression of BRCA1 
and COBRA1 is not dependent of each other.   
Total RNA samples from biologically duplicated 
cell lines of control (E), BRCA1 knockdown (-B), 
COBRA1 knockdown (-C), and BRCA1-COBRA1 
double knockdown (-B/C) were isolated and 
subjected to microarray analyses using Affymetrix 
HG-U133A GeneChipsTM with ~23K human gene 
transcripts. The LPE test was applied to identify the 
differentially expressed genes between the control and 
each of COBRA1 and/or BRCA1 knockdown cells. 
The program revealed 287 genes that were 
significantly affected by either BRCA1/COBRA1 alone 
or double knockdown, respectively (p<0.003; 
Supplemental Material).   
A hierarchical clustering analysis of the 287 
genes was carried out to further interrogate the 
relationship between BRCA1- and COBRA1-mediated 
gene regulation (Fig. 1B). A careful examination of the 
heat map revealed some interesting expression 
patterns among the 287 genes. In particular, depletion 
of BRCA1 or COBRA1 alone affected a large number 
of commonly regulated genes (a total of 151 genes), 
strongly suggesting a significant degree of functional 
overlap between the two proteins. Gene Ontology 
Analysis indicates that the BRCA1 and 
COBRA1-regulated genes are enriched with those 
involved in cell cycle control, cell proliferation and 
development, cell death, and cancer (Fig. 2).   
F o l l o w i n g  t h e  m i c r o a r r a y  s t u d y ,  w e  p e r f o r m e d  
quantitative RT-PCR (qRT-PCR) analysis to validate 
the effects of BRCA1 and COBRA1 on gene 
expression. The genes that were chosen for further 
verification include those that have been previously 
implicated in breast cancer, such as S100P [15] and 
TIMP-1 [16]. We first confirmed the changes in gene 
expression by using the same RNA prepared for the 
microarray analysis. As shown in Fig. 3, the 
expression level of all eight genes was altered by 
BRCA1/COBRA1 knockdown in a manner that was 
consistent with the microarray data (Supplemental 
Material). For example, expression of S100P was 
largely affected by COBRA1 or BRCA1 knockdown 
alone, respectively. Depletion of BRCA1 on top of 
COBRA1 did not lead to additional changes in mRNA 
abundance (compare “-C” with “-B/C” for S100P). On 
the other hand, the mRNA level of TIMP1 increased 
most substantially by the simultaneous knockdown of 
COBRA1 and BRCA1 (e.g. compare column “–B” and 
“–C” with “–B/C” for TIMP1), suggesting the 
involvement of both proteins in gene regulation at 
these loci. We were also able to verify the effect of 
COBRA1/BRCA1 knockdown on several 
down-regulated genes including SPINK5, ID1, and 
NBL1 (Fig. 3B).   
Among the BRCA1/COBRA1-coregulated genes, 
TIMP1 has been reported to be over-expressed in 
breast cancer [16,17] and especially in patients with 
advanced breast cancer [18], thus serving as a 
potential predictor for poor prognosis [19]. A recent 
study has also correlated TIMP1 expression with 
breast cancer that is metastasized to liver [20]. To 
confirm the TIMP1 results obtained from the stable 
knockdown cells, we used two different 
BRCA1-specific siRNA oligos (DO4 and DO7) to 
transiently knock down BRCA1 in COBRA1-depleted 
T47D cells. As shown in Fig. 4A and 4B, BRCA1 
knockdown by either oligo significantly increased 
TIMP1 expression. This result alleviates the concern 
over the possible secondary genetic changes that 
might have occurred in the stable BRCA1 knockdown 
cells due to the impaired DNA checkpoint function. It 
has been reported that TIMP1 expression is 
estrogen-stimulated [21]. Consistent with the 
published finding, we observed a modest (2-3 fold) 
stimulation of TIMP1 by estrogen treatment in both 
control and BRCA1/COBRA1-knockdown cells. 
Intriguingly, both estrogen-dependent and 
independent transcription of the TIMP1 gene was 
markedly elevated by the COBRA1/BRCA1 
knockdown (Fig. 4C).   Int. J. Biol. Sci. 2007, 3 
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Figure 2. Gene ontology of the COBRA1/BRCA1-regulated genes. The Ingenuity Gene Ontology Analysis tool is used to 
identify several biological pathways that are relatively enriched with COBRA1/BRCA1-regulated genes.  
 
Figure 3. Verification of the microarray results by real-time RT-PCR. Four different cell lines are compared: shEGFP (E; dark 
gray bars), shBRCA1 (-B; black stripe bars), shCOBRA1 (-C; white bars), and shBRCA1+shCOBRA1 (-B/C; black bars). The 
selected genes for verification include those that are up- (A) and down-regulated (B) by the depletion of BRCA1 and COBRA1. 
 
Figure 4. Further verification of the 
effect of BRCA1 knockdown on 
TIMP1 transcription. (A-B). 
Transient knockdown of BRCA1 
using BRCA1-specific siRNA oligo 
(DO4 in A and DO7 in B). Mock 
transfection and a luciferase-specific 
siRNA oligo were included as 
controls. siRNA oligos were 
transfected into EGFP(E) or 
COBRA1(-C) stable knockdown 
T47D cells. The immunoblots in Fig. 
4A show the extent of BRCA1 
depletion in the transient transfection 
experiment.  (B).  Control or 
BRCA1/COBRA1 knockdown cells 
were starved in medium containing 
charcoal-stripped serum. Vehicle or 
estradiol (E2; 10nM final 
concentration) was added for 24 hr, 
and RNA was harvested for qRT-PCR analysis of TIMP1 mRNA abundance. Int. J. Biol. Sci. 2007, 3 
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The effect of BRCA1 knockdown on TIMP1 
expression is consistent with the previously published 
work that indicates elevated TIMP1 expression in 
BRCA1 mutation-associated ovarian tumors and 
“BRCA1-like” sporadic tumors [22,23]. The same 
group also showed that ectopic expression of BRCA1 
in a BRCA1-deficient breast cancer cell line resulted in 
reduced TIMP-1 expression. In an independent study, 
ribozyme-mediated down-regulation of BRCA1 in a 
melanoma cell line also resulted in increased TIMP1 
expression [24]. Taken together, TIMP1 may serve as 
one of the molecular links between BRCA1-mediated 
transcriptional regulation and tumor metastasis.   
Many of the COBRA1-regulated genes identified 
in our previous and current work have been well 
documented for their roles in advanced breast cancer. 
For example, we recently demonstrated that COBRA1 
is recruited to, and regulates the activity of, the 
promoters of the trefoil factor (TFF) gene family 
(TFF1-3) [6]. TFF3 was also identified as a 
COBRA1-regulated gene in the current study 
(Supplemental Material). It is worth noting that both 
TFF1 and TFF3 are associated with breast cancer 
metastasis to bone [25] and advanced prostate cancer 
[26]. Similar association with breast cancer metastasis 
has also been reported for a number of 
COBRA1-regulated genes identified in the current 
microarray study, including S100P [27], MUC1 [28], 
and TIMP1. Combined with the finding that reduced 
COBRA1 expression is associated with metastatic and 
recurrent breast cancer [29], the effect of COBRA1 
knockdown on gene expression lends further support 
to the notion that COBRA1 plays an important role in 
suppressing breast cancer development. 
One of the most intriguing findings of the current 
work is the significant overlap of gene expression 
profiles between the BRCA1 and COBRA1-depleted 
cells. The data in the current study strongly suggest a 
joint action of COBRA1 and BRCA1 in modulating 
transcription of a group of common target genes. Both 
COBRA1 and BRCA1 are known to be associated with 
the RNA polymerase II (RNAPII) holoenzyme 
[2,10,13,30,31] as well as other factors involved 
transcriptional elongation and RNA processing 
[3,4,12,32,33]. In light of the physical association and 
functional commonality between COBRA1 and 
BRCA1, we propose that these two proteins may 
intimately communicate with each other in 
modulating the movement of the transcription 
elongation complex for a common set of target genes. 
Given the large overlap of the gene expression 
profiles in the COBRA1 and BRCA1-depleted cells, it 
is interesting to note that BRCA1-associated tumors 
are usually diagnosed as high-grade infiltrating ductal 
carcinoma, and that patients with BRCA1-associated 
breast tumors tend to have a poor prognosis [34]. 
Moreover, a recent report suggests a high incidence of 
brain metastasis in BRCA1-associated cancer cases 
[35]. These clinical features of BRCA1-associated 
tumors are reminiscent of the association of low 
COBRA1 expression with metastatic breast cancer 
[29]. It is conceivable that loss of COBRA1 and/or 
BRCA1 may result in aberrant expression of a 
common group of cancer metastasis-associated genes, 
which could account for the clinical outcomes in both 
cases. 
A significant proportion of the genes in the 
current microaray study are down-regulated in the 
COBRA1 and BRCA1 knockdown cells. This is 
somewhat unexpected as COBRA1 is best known for 
its role in transcriptional repression. It is possible that 
expression of this group of genes is indirectly affected 
by COBRA1 knockdown. Alternatively, COBRA1 
might act as a bi-functional protein to both repress 
and activate transcription. While more mechanistic 
studies may shed light on this issue, it is worth 
pointing out that COBRA1 is capable of inducing 
large-scale chromatin unfolding when targeted to 
specific regions of the mammalian genome [1]. 
Conceivably, the activity of COBRA1 in chromatin 
reorganization could account for a more direct role of 
COBRA1 in gene activation.   
In conclusion, combination of shRNA-mediated 
knockdown and gene expression profiling points to a 
large degree of functional commonality between 
COBRA1 and BRCA1 in transcriptional regulation. 
This finding provides functional relevance to the 
previously identified physical association between the 
two proteins. Furthermore, altered expression of 
multiple breast cancer-associated genes in the 
COBRA1/BRCA1 knockdown cells offers molecular 
insight into the roles of COBRA1 and BRCA1 in 
progression of breast cancer. 
Supplementary Material 
Primers used in the qRT-PCR for verification of 
COBRA1/BRCA1-regulated genes.  
[http://www.biolsci.org/v03p0486s1.pdf] 
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